Brief: Oragenics Partners With Avance Clinical For Phase II Concussion Trial In Australia
Brief: Oragenics Announces Notification Of Noncompliance With Additional NYSE American Continued Listing Standards
Brief: Oragenics Prepares Drug For Phase II Clinical Trials To Treat Concussion
Brief: Oragenics Announces Pricing Of Public Offering
Brief: Oragenics Announces Leadership Transition
Brief: Oragenics Announces Expiration Of Investment Banking Engagement Agreement
Brief: Oragenics Announces Termination Of At-The-Market Offering Program
Brief: Oragenics Inc Announces Termination Of At--Market Offering Program
Brief: Oragenics Completes Acquisition Of Odyssey Health’S Neurological Assets
Brief: Oragenics Inc - Board Approved An Increase In Size Of The Board Of Directors From Five To Seven
Oragenics rises on purchase of neurological therapies and tech
Brief: Oragenics Enters Into Agreement With Lantern Bioworks For Replacement-Therapy Assets
Brief: Oragenics Inc Announces Private Placement
Brief: Oragenics Project To Develop Variant-Agnostic Protein Antigen For Use
Brief: Oragenics Inc Says On April 4, Co Concluded That Some Of Co's Consolidated Financial Statements Should No Longer Be Relied Upon
Brief: Oragenics Announces Positive Results In Several Lantibiotics Compounds Against Mrsa And Vre
Brief: Oragenics Appoints Janet Huffman As Chief Financial Officer
Oragenics rises on license deal for intranasal COVID vaccine candidate
Brief: Oragenics Entered Sales Agreement With Agent